Cargando…

Dominant-negative SMARCA4 missense mutations alter the accessibility landscape of tissue-unrestricted enhancers

Mutation of SMARCA4 (BRG1), the ATPase of BAF (mSWI/SNF) and PBAF complexes, contributes to a range of malignancies and neurologic disorders. Unfortunately, the effects of SMARCA4 missense mutations have remained uncertain. Here we show that SMARCA4 cancer missense mutations target conserved ATPase...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodges, H. Courtney, Stanton, Benjamin Z., Cermakova, Katerina, Chang, Chiung-Ying, Miller, Erik L., Kirkland, Jacob G., Ku, Wai Lim, Veverka, Vaclav, Zhao, Keji, Crabtree, Gerald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909405/
https://www.ncbi.nlm.nih.gov/pubmed/29323272
http://dx.doi.org/10.1038/s41594-017-0007-3
Descripción
Sumario:Mutation of SMARCA4 (BRG1), the ATPase of BAF (mSWI/SNF) and PBAF complexes, contributes to a range of malignancies and neurologic disorders. Unfortunately, the effects of SMARCA4 missense mutations have remained uncertain. Here we show that SMARCA4 cancer missense mutations target conserved ATPase surfaces and disrupt the mechanochemical cycle of remodeling. We find that heterozygous expression of mutants alters the open chromatin landscape at thousands of sites across the genome. Loss of DNA accessibility does not directly overlap with Polycomb accumulation, but is enriched in “A compartments” at active enhancers, which lose H3K27ac but not H3K4me1. Affected positions include hundreds of sites identified as superenhancers in many tissues. Dominant-negative mutation induced pro-oncogenic expression changes, including increased expression of Myc and its target genes. Together, our data suggest that disruption of enhancer accessibility represents a key source of altered function in SMARCA4-mutated disorders in a wide variety of tissues.